How Biogen Made an Enemy of 1 of the Biggest Supporters of Its Alzheimer's Disease Drug
Many in the scientific community weren't thrilled that the U.S. Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) Aduhelm in treating Alzheimer's disease. They didn't think the data supported approval. However, there were some organizations that strongly supported FDA approval of the drug.
Now, Biogen has made a move that's angered one top advocate for FDA approval of Aduhelm. In this Motley Fool Live video recorded on June 16, Motley Fool contributors Keith Speights and Brian Orelli talk about what Biogen did to make an enemy of one of its strongest supporters.
Source Fool.com
